The National Institute for Health and Care Excellence is now recommending NHS use of Amgen’s Imlygic to treat advanced melanoma that has spread and can’t be surgically removed.
Regulatory
Nivolumab/Ipilimumab Combo Approved in Europe for Advanced Melanoma
The European Commission has approved the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) as a treatment for patients with unresectable or metastatic melanoma regardless of BRAF status, based on data from the CheckMate-069 and -067 studies.
FDA Approvals, New Biopsy Techniques Advance Head and Neck Melanoma Care
Advancements in biopsy techniques, as well as several recently approved new therapeutic agents, have made a significant difference in outcomes for patients with melanoma of the head and neck, says Carol Rossier Bradford, MD, a head and neck surgeon and professor of Otolaryngology at the University of Michigan Health System.
Cobimetinib in melanoma with BRAF V600 mutation: Indication of minor added benefit
Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. The Federal Joint Committee (G-BA) therefore commissioned the German Institute for Quality and Efficiency in Health Care (IQWiG) to examine whether cobimetinib in combination with vemurafenib has an added benefit over the appropriate comparator therapy vemurafenib alone.